Differentiated thyroid cancer: Focus on emerging treatments for radioactive iodine-refractory patients

Oncologist

Volumn 20, Issue 2, 2015, Pages 113-126

  Gruber, Joshua J ^a   Dimitrios Colevas, A ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

BRAF inhibitors; Follicular thyroid cancer; MEK inhibitors; Papillary thyroid cancer; Radioactive iodine refractory differentiated thyroid cancer; Tyrosine kinase inhibitors

Indexed keywords

AXITINIB; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; DABRAFENIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENVATINIB; MOTESANIB; PASIREOTIDE; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RADIOACTIVE IODINE; RAPAMYCIN; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; IMETELSTAT; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ALOPECIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER SURVIVAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; FATIGUE; FISTULA; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOPIGMENTATION; IC50; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SKIN MANIFESTATION; STOMATITIS; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; GENETICS; PATHOLOGY; THYROID NEOPLASMS;

DISEASE-FREE SURVIVAL; HUMANS; INDOLES; IODINE RADIOISOTOPES; MAP KINASE KINASE KINASE 1; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84922713837     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0313     Document Type: Article

References (123)

1. SEER stat fact sheets: Thyroid cancer. Available at http://seer.cancer.gov/statfacts/html/thyro.html. Accessed December 31, 2014.
2. Enewold L, Zhu K, Ron E et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009;18: 784-791.
3. Byrd JK, Yawn RJ, Wilhoit CS et al. Well differentiated thyroid carcinoma: Current treatment. Curr Treat Options Oncol 2012;13:47-57.
4. Nixon IJ, Whitcher MM, Palmer FL et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22: 884-889.
5. Banerjee M, Muenz DG, Chang JT et al. Treebased model for thyroid cancer prognostication. J Clin Endocrinol Metab 2014;99:3737-3745.
6. Schlumberger M, Tubiana M, De Vathaire F et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960-967.
7. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-2899.
8. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.
9. Kloos RT, Duvuuri V, Jhiang SM et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002;87:5817-5820.
10. Chen L, Shen Y, Luo Q et al. Pulmonary fibrosis following radioiodine therapy of pulmonary metastases from differentiated thyroid carcinoma. Thyroid 2010;20:337-340.
11. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638-1644.
12. Cooper DS, Doherty GM, Haugen BR et al. RevisedAmerican Thyroid Associationmanagement guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19: 1167-1214.
13. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
14. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13: 184-199.
15. Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
16. Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397.
17. Xu X, Quiros RM, Gattuso P et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-4567.
18. Fukushima T, Suzuki S, Mashiko M et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-6457.
19. Liu Z, Hou P, Ji M et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogenactivated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-3116.
20. Wang Y, Hou P, Yu H et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors. J Clin Endocrinol Metab 2007;92: 2387-2390.
21. Hou P, Liu D, Shan Y et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007;13:1161-1170.
22. Ricarte-Filho JC, Ryder M, Chitale DA et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles forBRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-4893.
23. Garcia-Rostan G, Zhao H, Camp RL et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003;21:3226-3235.
24. Basolo F, Pisaturo F, Pollina LE et al. N-ras mutation in poorly differentiated thyroid carcinomas: Correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000;10:19-23.
25. Fukahori M, Yoshida A, Hayashi H et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: New insights from a single center and a large patient cohort. Thyroid 2012;22:683-689.
26. Zhu Z, Gandhi M, Nikiforova MN et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71-77.
27. Manenti G, Pilotti S, Re FC et al. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 1994;30A:987-993.
28. Rabes HM, Demidchik EP, Sidorow JD et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications. Clin Cancer Res 2000;6: 1093-1103.
29. Santoro M, Thomas GA, Vecchio G et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 2000;82:315-322.
30. Klugbauer S, Demidchik EP, Lengfelder E et al. Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpointsinpapillarythyroidcarcinomasofchildren after Chernobyl. Oncogene 1998;16:671-675.
31. Abubaker J, Jehan Z, Bavi P et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in aMiddle Eastern population. J Clin Endocrinol Metab 2008;93:611-618.
32. Santarpia L, El-Naggar AK, Cote GJ et al. Phosphatidylinositol 3-kinase/Akt and ras/rafmitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008;93:278-284.
33. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun 2010;393:555-559.
34. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol 2010;163:747-755.
35. Murugan AK, Dong J, Xie J et al. Uncommon GNAQ, MMP8, AKT3, EGFR, andPIK3R1 mutationsin thyroid cancers. Endocr Pathol 2011;22:97-102.
36. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000;289:1357-1360.
37. Máximo V, Botelho T, Capela J et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br J Cancer 2005;92: 1892-1898.
38. Soares P, Máximo V, Sobrinho-Simöes M. Molecular pathology of papillary, follicular and Hürthle cell carcinomas of the thyroid. Arkh Patol 2003;65:45-47.
39. Kimura ET, Nikiforova MN, Zhu Z et al. High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
40. Jo YS, Li S, Song JH et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006;91:3667-3670.
41. Center for Drug Evaluation and Research, application no. 202324Orig1s000: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000PharmR.pdf. AccessedDecember 31, 2014.
42. Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-7283.
43. Center for Drug Evaluation and Research, application no. 203756Orig1s000: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203756Orig1s000PharmR.pdf. Accessed December 31, 2014.
44. Center for Drug Evaluation and Research, application no. 202806Orig1s000: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000PharmR.pdf. Accessed December 31, 2014.
45. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-4400.
46. Matsui J, Yamamoto Y, Funahashi Y et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producinghumansmall cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122: 664-671.
47. Polverino A, Coxon A, Starnes C et al.AMG706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-8721.
48. Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717-1723.
49. Center for Drug Evaluation and Research, application no. 22-465: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_PharmR.pdf. Accessed December 31, 2014.
50. Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation frommousetohumanwithpazopanib, amultikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6: 2012-2021.
51. Center for Drug Evaluation and Research, approval package for application no. NDA 21-923: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021923_s000_Nexavar_PharmR.pdf. Accessed December 31, 2014.
52. Wilhelm SM, Carter C, Tang L et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
53. Kitagawa D, Yokota K, Gouda M et al. Activitybased kinase profiling of approved tyrosine kinase inhibitors. Genes Cells 2013;18:110-122.
54. Center for Drug Evaluation and Research, approval package for application no. NDA 21-938 (GIST), NDA 21-968 (MRCC): Pharmacology review (s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_PharmR.pdf. Accessed December 31, 2014.
55. Yeh TC, Marsh V, Bernat BA et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007; 13:1576-1583.
56. Center for Drug Evaluation and Research, application no. 022405Orig1s000: Clinical pharmacology and biopharmaceutics review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf. AccessedDecember 31, 2014.
57. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655.
58. Center for Drug Evaluation and Research, application no. 22-334: Pharmacology review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_PharmR.pdf. Accessed December 31, 2014.
59. Shor B, Zhang WG, Toral-Barza L et al. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 2008;68:2934-2943.
60. Tafinlar (dabrafenib) [prescribing information]. Research Triangle Park, SC: GlaxoSmithKline; 2014.
61. Center for Drug Evaluation and Research, application no. 202429Orig1s000: Clinical pharmacology and biopharmaceutics review(s). Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000ClinPharmR.pdf. Accessed December 31, 2014.
62. Bollag G, Hirth P, Tsai J et al. Clinical efficacy of aRAFinhibitor needs broadtarget blockade inBRAFmutant melanoma. Nature 2010;467:596-599.
63. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-4713.
64. Locati L, Licitra L, Ou S-HI et al. Phase 2 trial of axitinib for advanced thyroid cancer: Preliminary activity results [abstract PP17]. Eur Arch Otorhinolaryngol 2012;269:1345.
65. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008;18:317-323.
66. Sherman SI, Jarzab B, Cabanillas ME et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(suppl):5503a.
67. Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.
68. Bible KC, Suman VJ, Molina JR et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010;11: 962-972.
69. Ho AL, Grewal RK, Leboeuf R et al. Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368:623-632.
70. Hayes DN, Lucas AS, Tanvetyanon T et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinomawith or without follicular elements. Clin Cancer Res 2012;18: 2056-2065.
71. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.
72. Chen L, Shen Y, Luo Q et al. Response to sorafenib at a low dose in patients with radioiodinerefractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011;21:119-124.
73. Brose MS, Nutting CM, Jarzab B et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 2013;31(suppl):04a.
74. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
75. Ahmed M, Barbachano Y, Riddell A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 2011;165:315-322.
76. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenibontumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-931.
77. Carr LL, Mankoff DA, Goulart BH et al. Phase II study of daily sunitinib in FDG-PET-positive, iodinerefractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-5268.
78. Cohen EE, Needles BM, Cullen KJ et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26(suppl):6025a.
79. Leboulleux S, Bastholt L, Krause T et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13: 897-905.
80. Brose MS, Cabanillas ME, Cohen EEW et al. An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (ptc) positive for the BRAF V600 mutation and resistant to radioactive iodine. Eur J Cancer 2013; 49(suppl 3):LBA28.
81. Brose MS, Nutting CM, Jarzab B et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014;384: 319-328.
82. Schlumberger M, Makoto T, Wirth L et al.Aphase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(suppl 5):LBA6008.
83. Schlumberger M, Jarzab B, Elisei R et al. Phase III randomized, double-blinded, placebo-controlled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes. Thyroid 2013;23:A-49-A-50.
84. Cabanillas ME, Brose MS, Holland J et al. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Thyroid 2014;24: 1508-1514.
85. Kim KB, Cabanillas ME, Lazar AJ et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF (V600E) mutation. Thyroid 2013;23:1277-1283.
86. Dadu R, Shah K, Waguespack SG et al. Efficacy and tolerability of vemurafenib in BRAFV600E positive papillary thyroid cancer (PTC). Thyroid 2013;23:A-95-A-96.
87. Falchook GS, Millward M, Hong D et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2014 [Epub ahead of print].
88. Lim SM, Chang H, Yoon MJ et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013;24:3089-3094.
89. Cediranib maleate with or without lenalidomide in treating patients with thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01208051. Accessed December 31, 2014.
90. Cabozantinib-S-malate in treating patients with refractory thyroid cancer. Available at https:// clinicaltrials.gov/ct2/show/NCT01811212. Accessed December 31, 2014.
91. A phase II trial of cabozantinib for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. Available at https://clinicaltrials.gov/ct2/show/NCT02041260. Accessed December 31, 2014.
92. Dabrafenib with or without trametinib in treating patients with recurrent thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01723202. Accessed December 31, 2014.
93. RAD001 for patients with radioiodine refractory thyroid cancer.Available at https://clinicaltrials.gov/ct2/show/NCT00936858. Accessed December 31, 2014.
94. Everolimus in treating patients with locally advanced or metastatic thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01164176. Accessed December 31, 2014.
95. Everolimus in treating patients with progressive or recurrent, unresectable, or metastatic thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01118065. Accessed December 31, 2014.
96. Study of everolimus and sorafenib in patients with advanced thyroid cancer who progressed on sorafenib alone. Available at https://clinicaltrials.gov/ct2/show/NCT01263951. Accessed December 31, 2014.
97. Evaluating the combination of everolimus and sorafenib in the treatment of thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01141309. Accessed December 31, 2014.
98. A trial of pasireotide and everolimus in adult patients with radioiodine-refractory differentiated and medullary thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01270321. Accessed December 31, 2014.
99. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01321554. Accessed December 31, 2014.
100. Pazopanib hydrochloride in treating patients with advanced thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00625846. Accessed December 31, 2014.
101. Phase II study of the optimal scheme of administration of pazopanib in thyroid carcinoma. Available at https://clinicaltrials.gov/ct2/show/NCT01813136. Accessed December 31, 2014.
102. AZD6244 in treating patients with papillary thyroid cancer that did not respond to radioactive iodine. Available at https://clinicaltrials.gov/ct2/show/NCT00559949. Accessed December 31, 2014.
103. Sunitinib in treating patients with thyroid cancer that did not respond to iodine I 131 and cannot be removed by surgery. Available at https://clinicaltrials.gov/ct2/show/NCT00381641. Accessed December 31, 2014.
104. Sutentadjunctive treatment of differentiated thyroid cancer (IIT Sutent). Available at https:// clinicaltrials.gov/ct2/show/NCT00668811. Accessed December 31, 2014.
105. Sunitinib malate in treating patients with iodine-refractory recurrent or metastatic thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00519896. Accessed December 31, 2014.
106. Combination of temsirolimus and sorafenib in the treatment of radioactive iodine refractory thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01025453. Accessed December 31, 2014.
107. Evaluation of efficacy, safety of vandetanib in patients with differentiatedthyroidcancer (VERIFY). Available at https://clinicaltrials.gov/ct2/show/NCT01876784. Accessed December 31, 2014.
108. A study of RO5185426 (vemurafenib) in patients with metastatic or unresectable papillary thyroid cancer positive for the BRAF V600 mutation. Available at https://clinicaltrials.gov/ct2/show/NCT01286753. Accessed December 31, 2014.
109. Vemurafenib neoadjuvant trial in locally advanced thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT01709292. Accessed December 31, 2014.
110. Schechter RB, Nagilla M, Joseph L et al. Genetic profiling of advanced RAI-resistant differentiated thyroid cancer and correlation with axitinib response. J Clin Oncol 2013;31(suppl):6066a.
111. Brose MS, Nutting C, Shong YK et al. Association between tumor BRAF andRASmutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: Subanalysis of the phase III DECISION trial. Eur J Cancer 2013;49(suppl 2):O3155.
112. Isham CR, Netzel BC, Bossou AR et al. Pazopanib resistance induced by in vitro selection of BHP2-7 papillary thyroid cancer cells is associated with acquired KRAS mutation and more aggressive in vivo phenotype. Thyroid 2013;23:A-78.
113. Ball DW, Sherman SI, Jarzab B et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012;30(suppl):5518a.
114. Study of AG-013736 in patients with 131Irefractory thyroid cancer. Available at https://clinicaltrials.gov/ct2/show/NCT00389441. Accessed December 31, 2014.
115. Nexavar (sorafenib) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2013.
116. Blevins DP, Dadu R, Hu M et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 2014;24:918-922.
117. Turan N, Benekli M, Ozturk SC et al. Sunitiniband sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Ann Pharmacother 2012;46:e27.
118. Brzezniak C, Szabo E. Images in clinical medicine. Sunitinib-associated hair depigmentation. N Engl J Med 2014;370:e27.
119. Dadu R, Devine C, Hernandez M et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014;99: 2086-2094.
120. Massicotte MH, Brassard M, Claude-Desroches M et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: A retrospective study of the TUTHYREF network. Eur J Endocrinol 2014;170:575-582.
121. Rothenberg SM, McFadden DG, Palmer E et al. Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study. J Clin Oncol 2013;31(suppl): 6025a.
122. Flaherty KT, Infante JR, Daud A et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367: 1694-1703.
123. Salama AK, Kim KB. MEK inhibition in the treatment of advanced melanoma. Curr Oncol Rep 2013;15:473-482.